BioSpace News Archive

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced a worldwide, exclusive license agreement with Genentech, a member of the Roche Group, for rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved “inducement” grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

- The Global Cannabis Partnership (GCP) is pleased to announce today the addition of seven new Members as it continues to grow internationally, bringing its total membership number to 31.

Pioneering Service Delivers Comprehensive Insight into Biological Target Profiling

SonarMD partners with payer organizations and specialist groups to improve care for “high beta” patients

A renowned competitive intelligence solutions provider, Infiniti Research, has announced the completion of their competitive pricing strategy engagement for a medical device manufacturer. T

The global infectious disease therapeutics market is expected to post a CAGR of over 4% during the period 2019-2023, according to the latest market research report by Technavio.

A little over a year after raising over EUR 28 million in a private placement, Q3 Medical Devices Limited (“Q3 Medical” or the “Company”) based in Dublin, Ireland today announced a new initiative to raise EUR 50 million in a Pre-IPO round

Largest dental support organization continues nationwide growth

First U.S. clinical trial initiated with patient-operated home OCT device for monitoring patients diagnosed with exudative age-related macular degeneration (eAMD)